Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT03876509 Recruiting - Clinical trials for Pulmonary Hypertension

Non-invasive Diagnosis of Pulmonary Hypertension by Impedance Cardiography

Start date: July 4, 2018
Study type: Observational

The goal of the study is to prospectively evaluate Impedance Cardiography as a tool to detect pulmonary hypertension. According to our hypothesis Impedance Cardiography is a valuable method to differentiate patients without pulmonary hypertension from patients with pulmonary hypertension. The main objective is to determine the sensitivity and specificity in comparison to the gold standard right heart catheterization.

NCT ID: NCT03854071 Suspended - Clinical trials for Coronary Artery Disease

Development of Novel Physiological CMR Methods in Health and Disease

Start date: July 30, 2018
Phase: N/A
Study type: Interventional

Physiological cardiovascular stress test plays a crucial role in the assessment of patients with suspected heart disease. There are several methods of cardiac physiological stress tests and each of them offer varied insight into cardiac physiological adaptation: passive leg raise, intra-venous fluid challenge, pharmacological stressors and physical exercise stress test. Echocardiography, which is the mainstay for the non-invasive rest/stress assessment of the left ventricular (LV) haemodynamics has several limitations. Novel methods of CMR imaging allow to map intra-cardiac flow in three-dimension using novel flow acquisitions. These novel flow acquisitions are called four-dimensional flow CMR, where the fourth dimension is time. Additionally, traditional cine CMR imaging for functional assessment can now be done without breath-holds using advanced acceleration methods, allowing them to be used during exercise. A comprehensive understanding of functional-flow coupling at rest, during increased pre-load (fluid challenge) to the heart or during exercise, is lacking in the literature. There is an important need to validate these novel CMR methods for developing mechanistic insight into physiological cardiac adaptation to increased pre-load or to exercise in health and how it alters in heart disease.

NCT ID: NCT03835676 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension

Start date: May 1, 2019
Phase: Phase 4
Study type: Interventional

In a group of patients with PAH treated with treprostinil, the current study aims to investigate the effect of treatment on RV structure and function; and correlate changes in RV structure and function with: World Health Organisation (WHO) class, Six-minute walk test, Quality of life (QoL), and Pre-specified biomarkers (N-terminal B-type natriuretic peptide (NT-ProBNP), Tissue growth factor-B B-type natriuretic peptide BNP, and Profibrotic markers)

NCT ID: NCT03821766 Not yet recruiting - Heart Failure Clinical Trials

Haemodynamic Abnormalities Recorded With Cardiac Catheterization Along With Body's Surface Micro-accelerometers (KT-KCG)

Start date: February 18, 2019
Study type: Observational

The ballistocardiography (BCG) and the seismocardiography (SCG) are old techniques recording the vibrations at the skin level generated by the acceleration and displacement of the blood and cardiac mass at each cardiac contraction. The former records the acceleration near the subject's center of mass, the latter at the local chest wall. So far, the unclear physiological origin of those acceleration signals has led to important ambiguities in their scientific and clinical interpretation. Therefore, several ongoing studies would aim to highlight the physiological genesis of those acceleration-induced signals. Indeed, the main objective of this study is to correlate the BCG and SCG signals recorded at the body surface with several haemodynamic parameters recorded invasively during a cardiac catheterisation, pulmonary pressure, wedge pressure, cardiac output to cite a few.

NCT ID: NCT03809156 Recruiting - Clinical trials for Pulmonary Hypertension

Upfront Combination Pulmonary Arterial Hypertension Therapy

Start date: April 26, 2016
Phase: Phase 4
Study type: Interventional

To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).

NCT ID: NCT03794583 Enrolling by invitation - Clinical trials for Chronic Obstructive Pulmonary Disease

Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in subjects who have completed Study RIN-PH-304. This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

NCT ID: NCT03787082 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension

Start date: February 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in volunteers with PH in the breakdown of oral nitrate and effect on hemodynamics.

NCT ID: NCT03780803 Recruiting - Clinical trials for Pulmonary Hypertension

Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD

Start date: February 1, 2016
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and body mass composition in patients with pulmonary arterial hypertension (PAH) or left ventricular heart failure with reduced ejection fraction - HFREF), or ischemic heart disease and evaluation the number of stem cells, natural lymphoid cells and distribution of subpopulations of monocytes (including proangiogenic monocytes) in examined persons and evaluation of theirs eventual influence of the course of disease.

NCT ID: NCT03763045 Active, not recruiting - Clinical trials for Pulmonary Hypertension

Sildenafil in Hemodialysis Patients With Pulmonary Hypertension

Start date: December 2, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Sildenafil is a phosphodiesterase inhibitor that can exert a nitric oxide-mediated vasodilation effect, so it's considered one of the preferred agents especially in hypoxia induced pulmonary hypertension, can achieve pulmonary vasodilation by enhancing sustained levels of cyclic guanosine monophosphate (cGMP) and nitric oxide. Despite the potential burden of pulmonary hypertension in hemodialysis patients, such agent like sildenafil has limited studies about optimum dose, safety and long term efficacy in End stage renal disease patients on hemodialysis with pulmonary hypertension

NCT ID: NCT03762577 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

Effects of Ground-based Walking Training in Pulmonary Hypertension

Start date: September 12, 2018
Phase: N/A
Study type: Interventional

Pulmonary Hypertension (PH) is a hemodynamic and physiopathological condition that is defined as an increase in pulmonary artery pressure ≥25 mmHg when measured at resting with symptoms such as dyspnea, fatigue, chest pain, and syncope. PH characterized by decreased exercise capacity, quality of life, peripheral muscle strength, balance, and physical inactivity. It is recommended that patients with PH should be included in cardiopulmonary rehabilitation programs in addition to medical treatment. Ground-based walking training is a safe and effective method for COPD patients. In the literature, there are no studies evaluating the effects of ground-based walking training in PH patients. The aim of this project is to determine the effect of ground-based walking training on physical activity, exercise capacity, balance, peripheral muscle strength and quality of life in patients with PH.